Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
89.17 EUR | -0.77% | -0.96% | -0.69% |
05-27 | Sanofi Gets US FDA’s Priority Review for Expanded Use of Blood Cancer Drug Sarclisa | MT |
05-27 | Sanofi: FDA grants priority review in myeloma | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.69% | 122B | |
+38.51% | 727B | |
+32.14% | 594B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+14.89% | 243B | |
+7.68% | 205B | |
-6.01% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Sanofi Plans EUR1 Billion Investments in France